Edwards Lifesciences (NYSE: EW) + announced positive results from two real-world studies evaluating its Sapien transcatheter aortic valve replacement (TAVR) system.
Results came from the TVT Registry data and continued to demonstrate strong outcomes. Edwards presented the data at Cardiovascular Research Technologies (CRT) 2024.
A study of the latest TAVR technology, the Sapien 3 Ultra Resilia valve found lower rates of paravalvular leak (PVL) at 30 days when compared to the Sapien 3 and Sapien 3 Ultra valves. Results also showed lower echo-derived gradients and larger effective orifice areas across all valve sizes.
Edwards’ second study showed that its small Sapien TAVR valves demonstrate equal outcomes at three years compared to larger Sapien valve sizes.
“These real-world data further add to the robust body of evidence on the…